Condition: Multiple Myeloma · Sponsor: Peking University People's Hospital
This study evaluates the maintenance strategy based on risk stratification and MRD status after stem cell transplantation. This is a single-arm, multicenter, prospective study. Participants who are R2-ISS 1,2 and MRD negative receive the single drug lenalidomide maintenance. In other circumstances, for example, patients who are R2-ISS 3 or 4 will receive daratumumab combined with lenalidomide regardless of MRD status, while patients with MRD positivity will also receive daratumumab plus lenalidomide maintenance.
This description comes directly from the study's public registry record.
Yang Dr, M.D. · +86-10-88326542 · pkuphliuyang@bjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Fuxing Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Harbin Medical University | Harbin, Heilongjiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06697483